Healthcare / Medical Instruments & SuppliesUpdated 2026-05-10 22:07 UTC

RGEN stock hub

Repligen Corporation has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RGENis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RGEN

In the news

Latest news · RGEN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E58.8

P25 12.6P50 18.3P75 33.7

Trailing P/E135.7

P25 15P50 23.3P75 38.5

ROE2.5

P25 -106.6P50 -46.9P75 -3.1

ROIC2.5

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RGEN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

265

Groups with data

Currency

USD

Showing 265 of 265 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000730272
Company name	Repligen Corporation
Country	United States
Country code	US
Cusip	759916109
Employees	2,000
Employees Change	222%
Employees Change Percent	12.49
Enterprise value	$6.9B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Medical Instruments & Supplies
Isin	US7599161095
Last refreshed	2026-05-10
Market cap	$7B
Market cap category	Mid-Cap
Price	$123
Price currency	USD
Rev Per Employee	381,669.5x
Sector	Healthcare
Sic	2836
Symbol	RGEN
Website	https://www.repligen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	0.74%
EV Earnings	133.61x
EV Sales Forward	7.88x
EV/EBIT	126.16x
EV/EBITDA	51.16x
EV/FCF	64.76x
EV/Sales	9x
FCF yield	1.52%
Forward P/E	58.77x
P/B ratio	3.31x
P/E ratio	135.69x
P/S ratio	9.12x
PE Ratio10 Y	265.09x
PE Ratio3 Y	782.03x
PE Ratio5 Y	432.2x
PEG ratio	2.92x
PS Forward	7.99x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	7.13%
EBITDA Margin	17.59%
FCF margin	13.89%
Gross margin	53.14%
Gross Profit	$405.6M
Gross Profit Growth	21.92%
Gross Profit Growth Q	18.51%
Gross Profit Growth3 Y	-0.77%
Gross Profit Growth5 Y	10.08%
Net Income	$51.4M
Net Income Growth Q	42.93%
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Net Income Growth3 Y	-30.68%
Net Income Growth5 Y	-8.37%
Pretax Margin	7.36%
Profit Margin	6.73%
Profit Per Employee	$25,699
Profitable Years	1
ROA	1.18
Roa5y	2.61
ROCE	1.94
ROE	2.51
Roe5y	4.18
ROIC	2.47
Roic5y	5.39

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	16.75%
Cagr15y	25.63%
Cagr1y	-2.7%
Cagr20y	20.02%
Cagr3y	-8.31%
Cagr5y	-8.05%
EPS Growth Q	47.87
EPS Growth Quarters	5
EPS Growth Years	1
EPS Growth3 Y	-30.48
EPS Growth5 Y	-8.97
FCF Growth	-15.03%
FCF Growth Q	106.13%
FCF Growth3 Y	4.11%
FCF Growth5 Y	23.81%
OCF Growth	-10.29%
OCF Growth Q	88.57%
OCF Growth10 Y	25.44%
OCF Growth3 Y	-6.54%
OCF Growth5 Y	15.95%
Revenue Growth	17.36x
Revenue Growth Q	14.83x
Revenue Growth Quarters	7x
Revenue Growth Years	2x
Revenue Growth3 Y	0.12x
Revenue Growth5 Y	12.01x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.26
Assets	$2.9B
Cash	$784.5M
Current Assets	$1.2B
Current Liabilities	$126.2M
Debt	$687.6M
Debt EBITDA	$4.02
Debt Equity	$0.33
Debt FCF	$6.48
Equity	$2.1B
Interest Coverage	2.32
Liabilities	$825.3M
Long Term Assets	$1.8B
Long Term Liabilities	$699.1M
Net Cash	$96.9M
Net Cash By Market Cap	$1.39
Net Cash Growth	616.21%
Net Debt EBITDA	$-0.72
Net Debt Equity	$-0.05
Net Debt FCF	$-0.91
Tangible Book Value	$630.4M
Tangible Book Value Per Share	$11.18
WACC	9.62

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.2
Inventory Turnover	2.15
Net Working Capital	$271.7M
Quick ratio	7.45
Working Capital	$1B
Working Capital Turnover	$0.8

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.01%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	370.32%
1Y total return	-2.7%
200-day SMA	138.2
3Y total return	-22.91%
50-day SMA	120.5
50-day SMA vs 200-day SMA	50under200
5Y total return	-34.26%
All Time High	327.3
All Time High Change	-62.28%
All Time High Date	2021-09-23
All Time Low	0.5
All Time Low Change	24,592%
All Time Low Date	1996-07-15
ATR	6.06
Beta	1.09
Beta1y	1.43
Beta2y	0.97
Ch YTD	-24.66
High	126.8
High52	175.8
High52 Date	2026-01-06
High52ch	-29.76%
Low	121.3
Low52	109.5
Low52 Date	2026-04-23
Low52ch	12.75%
Ma50ch	2.45%
Premarket Change Percent	-0.34
Premarket Price	$126
Premarket Volume	8,864
Price vs 200-day SMA	-10.67%
RSI	51.8
RSI Monthly	44.21
RSI Weekly	44.23
Sharpe ratio	0.07x
Sortino ratio	0.24
Total Return	-1.01%
Tr YTD	-24.66
Tr15y	2,963.52%
Tr1m	7.09%
Tr1w	5.34%
Tr3m	-13.17%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Ratings	Buy
Earnings EPS Estimate	$0.38
Earnings EPS Estimate Growth	-2.56
Earnings Revenue Estimate	191,960,960x
Earnings Revenue Estimate Growth	13.47x
Operating Income	$54.4M
Operating Income Growth	32.69
Operating Income Growth Q	102.2
Operating Income Growth3 Y	-29.21
Operating Income Growth5 Y	-11.6
Operating margin	7.13
Price target	$167
Price Target Change	$35.13

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	53,369,073%
Float Percent	94.61%
Shares Insiders	0.46%
Shares Institutions	114.24%
Shares Out	56,407,740
Shares Qo Q	0.01%
Shares Yo Y	1.01%
Short Float	10.28%
Short Ratio	6.44
Short Shares	9.73

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$72.4M
Average Volume	1,135,168.15x
Bv Per Share	37.33
CAPEX	$-24.7M
Ch10y	370.3
Ch15y	2,963.5
Ch1m	7.09
Ch1w	5.34
Ch1y	-2.7
Ch20y	3,746.1
Ch3m	-13.17
Ch3y	-22.91
Ch5y	-34.26
Ch6m	-13.56
Change	-2.35%
Change From Open	-1.88
Close	126.4
Days Gap	-0.47
Depreciation Amortization	79,803,000
Dollar Volume	117,102,303.8
Earnings Date	2026-05-05
Earnings Time	bmo
EBIT	$54.4M
EBITDA	$134.2M
EPS	$0.91
F Score	7
FCF	$106M
FCF EV Yield	1.54x
FCF Per Share	$1.88
Financing CF	-15,718,000
Fiscal Year End	December
Founded	1,981
Goodwill	1,106,874,000
Graham Number	27.64476
Graham Upside	-77.61
Income Tax	$4.8M
Investing CF	-228,354,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Lynch Fair Value	$4.55
Lynch Upside	-96.32
Ma150	143.7
Ma150ch	-14.07%
Ma20	123.4
Ma20ch	0.03%
Net CF	-112,589,000
Next Earnings Date	2026-07-28
Open	125.8
Optionable	Yes
P FCF Ratio	65.67
P OCF Ratio	53.28
Position In Range	39.5
Post Close	123.5
Postmarket Change Percent	0.11
Postmarket Price	$124
Ppne	287,105,000
Pre Close	126.4
Price Date	2026-05-08
Price EBITDA	$51.88
Ptbv Ratio	11.05
Relative Volume	0.84x
Revenue	763,339,000x
SBC By Revenue	4.41x
Share Based Comp	33,654,000
Tax By Revenue	0.63x
Tax Rate	8.57%
Tr20y	3,746.11%
Tr6m	-13.56%
Us State	Massachusetts
Volume	948,504
Z Score	6.54

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RGEN pay a dividend?

Capital-return profile for this ticker.

Performance

RGEN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RGEN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+114.2%

Float: +94.6% of shares outstanding

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RGEN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.8

Neutral momentum band

Price vs 200-day MA

-10.7%

50/200-day relationship not available

Beta (5Y)

1.09

Moves roughly with the market

Sharpe ratio

0.07

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RGEN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RGEN stock rating?

Repligen Corporation is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RGEN analysis?

The full report lives at /stocks/RGEN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RGEN?

The latest report frames RGEN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RGEN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.